MedTrace Logo

Innovative "Scoring System" in Breast Cancer Post Neoadiuvant Chemotherapy

NCT05213403 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 255

Last updated 2022-01-28

No results posted yet for this study

Summary

Our aim is to create a Scoring System (SS) able of guaranteeing radical oncology by completely removing cancer and aesthetic outcomes in line with the needs or expectations of the patients that helps surgeons to decide the type of surgery in patients undergoing NACT.

Secondary outcome is to assess the ability of the score to avoid neoplastic relapses by evaluating:

* Loco-regional disease free-survival (LR-DFS): months between start of NACT and date of a neoplastic recurrence in residual mammary gland, in ipsilateral chest wall or in ipsilateral axilla.
* Distant disease-free survival (DDFS): months between start of NACT and date of onset of visceral or skeletal metastases.
* Overall survival (OS): months from the start of NACT to death or last follow-up.

Conditions

  • Early Breast Cancer

Interventions

DIAGNOSTIC_TEST

Evaluation with new scoring system

Evaluate whether patients who have received surgery in line with the developed "scoring system" have a better aesthetic and oncological outcomes

Sponsors & Collaborators

  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS

    lead OTHER

Principal Investigators

  • Gianluca Franceschini, Prof. · IRCCS Policlinico Agostino Gemelli - Roma

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-01-01
Primary Completion
2021-03-31
Completion
2021-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05213403 on ClinicalTrials.gov